Fig. 1

CV risk score^* according to metformin use at baseline. The light gray color indicates the overlap between the metformin and no-metformin subgroups. ^*Derived from a prediction model developed using independent data sets from the liraglutide CV outcomes trial and previously applied to SUSTAIN 6 and PIONEER 6 [19]. CV cardiovascular